Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Capital Expenditures (2024 - 2025)

Historic Capital Expenditures for Indivior Pharmaceuticals (INDV) over the last 4 years, with Q3 2025 value amounting to $20.0 million.

  • Indivior Pharmaceuticals' Capital Expenditures rose 18571.43% to $20.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.0 million, marking a year-over-year increase of 13200.0%. This contributed to the annual value of $29.0 million for FY2024, which is 26250.0% up from last year.
  • According to the latest figures from Q3 2025, Indivior Pharmaceuticals' Capital Expenditures is $20.0 million, which was up 18571.43% from $17.0 million recorded in Q2 2025.
  • In the past 5 years, Indivior Pharmaceuticals' Capital Expenditures registered a high of $20.0 million during Q3 2025, and its lowest value of -$2.0 million during Q3 2022.
  • In the last 4 years, Indivior Pharmaceuticals' Capital Expenditures had a median value of $5.0 million in 2025 and averaged $6.6 million.
  • In the last 5 years, Indivior Pharmaceuticals' Capital Expenditures changed by 0.0% in 2023 and then soared by 50000.0% in 2024.
  • Indivior Pharmaceuticals' Capital Expenditures (Quarter) stood at $9.0 million in 2022, then soared by 33.33% to $12.0 million in 2023, then soared by 33.33% to $16.0 million in 2024, then rose by 25.0% to $20.0 million in 2025.
  • Its Capital Expenditures stands at $20.0 million for Q3 2025, versus $17.0 million for Q2 2025 and $5.0 million for Q1 2025.